IMBdx Inc

461030

Company Profile

  • Business description

    IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.

  • Contact

    131 Gasandigital 1-ro
    21st Floor BYC Highcity Building A
    Geumcheon-gu
    Seoul08506
    KOR

    T: +82 269512906

    https://www.imbdx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    58

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,931.7031.80-0.35%
CAC 407,800.8833.70-0.43%
DAX 4023,970.36247.14-1.02%
Dow JONES (US)44,837.5664.36-0.14%
FTSE 1009,081.4438.87-0.43%
HKSE25,313.22248.91-0.97%
NASDAQ21,178.5870.270.33%
Nikkei 22540,655.54342.73-0.84%
NZX 50 Index12,893.5317.21-0.13%
S&P 5006,389.771.130.02%
S&P/ASX 2008,670.4027.30-0.31%
SSE Composite Index3,598.400.460.01%

Market Movers